Vanucizumab Anti-Human VEGFA Recombinant Antibody; RO5520985
产品编号：Bellancom-P99330| CAS NO：1448221-05-3
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，
Vanucizumab Anti-Human VEGFA Recombinant Antibody; RO5520985
| 产品介绍 | Vanucizumab 是一种首创的双特异性 IgG1 单克隆抗体，可同时阻断 VEGF-A 和血管生成素-2 (Ang-2) 与其受体相互作用。 Vanucizumab 具有抗血管生成和抗癌作用。 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 生物活性 | Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects. | ||||||||
| 体外研究 | |||||||||
| 体内研究 |
Vanucizumab (20mg /kg;i.p。每周1次;6周) 显示肿瘤生长抑制和诱导肿瘤停滞。 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||
| 体内研究 |
Vanucizumab (20mg /kg;i.p。每周1次;6周) 显示肿瘤生长抑制和诱导肿瘤停滞。 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||
| 性状 | |||||||||
| 溶解性数据 | |||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. | ||||||||
| 参考文献 |
|
浙公网安备 33010802013016号